Rocavorexant
Rocavorexant ( ; developmental code names C4X-3256 and INDV-2000) is an orexin OX 1 receptor antagonist which is under development for the treatment of opioid-related disorders and other substance-related disorders.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Rocavorexant ( ; developmental code names C4X-3256 and INDV-2000) is an orexin OX 1 receptor antagonist which is under development for the treatment of opioid-related disorders and other substance-related disorders. It is taken orally. The drug is under development by C4X Discovery and/or Indivior.
As of May 2026, development for all indications has been suspended. The drug has reached phase 2 clinical trials for opioid-related disorders and phase 1 trials for substance-related disorders.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372045974 under CC BY-SA 4.0; modifications have been made.